Longeveron to report Q1 2026 financial results and host conference call on May 13

Longeveron Inc., a clinical-stage biotech company specializing in cellular therapies for rare pediatric and aging-related conditions, will release its Q1 2026 financial results on May 13 after market close. The company will also provide a business update and hold a conference call and webcast at 4:30 p.m. ET the same day. Longeveron's lead product, laromestrocel, targets multiple serious diseases and has received several FDA designations, highlighting its potential. Investors can expect updates on ongoing trials and company progress during the call.